Amgen prevails against Sanofi and Regeneron

A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha (evolocumab), rejecting a challenge brought by two competitors.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

A deep dive into Regeneron v Kymab

8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.

Americas

Sanofi, Regeneron prevail against Amgen at EPO

30 October 2020 French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.

Biotechnology

Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms

6 October 2020 Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Amgen prevails against Sanofi and Regeneron

More on this story

Editor's picks

Editor's picks

More features